| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
1 Leukemia Section, 2 Department of Medicine, and 3 Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Experimental Design: VX-710 modulation of uptake, retention, and cytotoxicity of mitoxantrone, daunorubicin, doxorubicin, topotecan, and SN38 was studied in cell lines overexpressing Pgp, MRP-1 and wild-type (BCRPR482) and mutant (BCRPR482T) BCRP.
Results: In 8226/Dox6 cells (Pgp), VX-710 increased mitoxantrone and daunorubicin uptake by 55 and 100%, respectively, increased their retention by 100 and 60%, respectively, and increased their cytotoxicity 3.1- and 6.9-fold, respectively. In HL60/Adr cells (MRP-1), VX-710 increased mitoxantrone and daunorubicin uptake by 43 and 130%, increased their retention by 90 and 60%, and increased their cytotoxicity 2.4- and 3.3-fold. In 8226/MR20 cells (BCRPR482), VX-710 increased mitoxantrone uptake and retention by 60 and 40%, respectively, and increased cytotoxicity 2.4-fold. VX-710 increased daunorubicin uptake and retention by only 10% in 8226/MR20 cells, consistent with the fact that daunorubicin is not a substrate for BCRPR482, but, nevertheless, it increased daunorubicin cytotoxicity 3.6-fold, and this increase was not associated with intracellular drug redistribution. VX-710 had little effect on uptake, retention, or cytotoxicity of mitoxantrone, daunorubicin, doxorubicin, topotecan, or SN38 in MCF7 AdVP3000 cells (BCRPR482T).
Conclusions: VX-710 modulates Pgp, MRP-1, and BCRPR482, and has potential as a clinical broad-spectrum MDR modulator in malignancies such as the acute leukemias in which these proteins are expressed.
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Cell membrane proteins that are overexpressed in multidrug-resistant cells include P-glycoprotein (Pgp; Ref. 2 ), multidrug resistance protein (MRP-1; Ref. 3 ), and breast cancer resistance protein (BCRP; Ref. 4 ). These proteins are members of the ATP-binding cassette superfamily of transport proteins (1) , but they differ in structure and in substrate specificity. Pgp is a 170,000 kDa protein that confers cross-resistance to many natural product antitumor agents, including anthracyclines, mitoxantrone, epipodophyllotoxins, and taxanes (2) . MRP-1 is structurally similar to Pgp but shares only 15% amino acid sequence identity (3) ; it also confers resistance to anthracyclines, mitoxantrone, and epipodophyllotoxins but differs from Pgp in the level of resistance to taxanes (5 , 6) . BCRP also confers resistance to mitoxantrone (4) , but transport of anthracyclines was recently found to depend on mutations that alter amino acid 482 of the molecule (7) . Anthracyclines are not transported by wild-type BCRP, with arginine at the amino acid 482 position (BCRPR482), which is present in 8226/MR20 myeloma cells and in acute leukemia patient samples (8 , 9) . In contrast, they are transported by a mutant BCRP with threonine instead of arginine at the amino acid 482 position (BCRPR482T), which is present in MCF7 AdVP3000 breast cancer cells. In addition, unlike Pgp and MRP-1, BCRP confers resistance to camptothecin analogues, including topotecan and SN38 (10 , 11) . A fourth MDR protein, lung resistance protein, is not an ATP-binding cassette transport protein, but rather a so-called vault protein; it mediates nuclear-cytoplasmic drug distribution rather than cellular drug efflux (12) .
Although most MDR modulators used in the laboratory and in the clinic are specific for individual drug efflux proteins, the clinically applicable pipecolinate derivative VX-710 {biricodar; (S)-N-[2-Oxo-2-(3,4,5-trimethoxyphenyl)-acetyl]piperidine-2-carboxylic acid 1,7-bis(3-pyridyl)-4-heptyl ester; Incel, Vertex Pharmaceuticals Incorporated, Cambridge, MA} is known to have activity against both Pgp and MRP-1 (13 , 14) . Here we demonstrate that VX-710 also has activity in increasing drug uptake and retention and reversing drug resistance mediated by wild-type BCRP (BCRPR482). These data provide support for further clinical development of VX-710 and testing in malignancies such as the acute leukemias in which these MDR proteins are expressed (8 , 9 , 15) .
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
MDR Protein Expression.
To detect Pgp, 0.5 to 1 x 106 cells were washed in PBS and incubated for 20 min on ice with MRK16 antibody (Kamiya Biomedical Company, Tukwila, WA) or mouse IgG2a isotype control matched according to immunoglobulin protein content, as described previously (21)
. Cells were then washed in PBS, incubated with phycoerythrin-conjugated goat-antimouse antibody for 20 min on ice, washed again in PBS, and stored on ice until analysis.
To detect MRP-1, 0.5 to 1 x 106 cells were fixed in 3.7% (w/v = 10% v/v) formaldehyde for 10 min at room temperature, pelleted, resuspended in ice-cold methanol for 10 min, and washed three times in cold PBS with 1% BSA. Cells were then incubated for 40 min with the MRPm6 monoclonal antibody (Kamiya) or IgG1 isotype control, washed in PBS with 0.01% Tween, incubated with fluorescein-conjugated goat-antimouse antibody for 40 min on ice, washed again in PBS with 0.01% Tween, and then stored on ice until analysis.
BCRP staining was described previously (19) . Briefly, 0.5 to 1 x 106 cells were washed in PBS, fixed in 3.7% (w/v = 10% v/v) formaldehyde for 10 min at room temperature, pelleted, resuspended in ice-cold methanol for 10 min, washed in PBS with 0.01% Tween and blocked with pooled human serum. The cells were then incubated for 60 min on ice with BXP-21 or BXP34 monoclonal antibody (gifts from Dr. R. J. Scheper, Free University Hospital, Amsterdam, the Netherlands; Ref. 22 ) in 2% BSA at a final concentration 2.5 µg/ml or with mouse IgG1 (BXP-34) or IgG2a (BXP-21) isotype control, matched according to immunoglobulin protein content. Cells were then washed in PBS with 0.01% Tween, incubated with fluorescein-conjugated goat-antimouse antibody for 20 min on ice, washed in PBS with 0.01% Tween, and stored on ice.
Drugs.
Drugs studied included mitoxantrone (Sigma, St. Louis, MO), daunorubicin (Sigma), doxorubicin (Sigma), topotecan (LKT Laboratories, St Paul, MN) and SN38 (Pharmacia, Kalamazoo, MI). In studies of drug uptake and/or retention, mitoxantrone, daunorubicin, and doxorubicin were used at a concentration of 3 µM, topotecan at 100 µM, and SN38 at 2.5 µM. We have previously demonstrated that mitoxantrone at a concentration of 3 µM can be used to study modulation of drug retention in cell lines overexpressing Pgp, MRP-1, and BCRP with a standard flow cytometry setup (19)
. For cytotoxicity studies, cells were exposed to a 5-log range of drug doses with half-log increments. Drugs were prepared from frozen 5 mM stock solutions.
Modulators.
VX-710 was compared with PSC-833 (Novartis Pharmaceutical Corporation, East Hanover, NJ), p-[dipropylsulfamoyl]benzoic acid (Probenecid; Sigma), and fumitremorgin C (FTC; gift from Dr. Susan Bates, National Cancer Institute, NIH, Bethesda, MD), which are modulators specific for Pgp, MRP-1, and both wild-type and mutant BCRP, respectively. VX-710 and PSC-833 were studied at 2.5 µM, probenecid at 1 mM, and FTC at 10 µM; these concentrations were based on previous reports (13
, 14
, 21
, 23, 24, 25)
.
Modulation of Drug Uptake and Drug Retention.
To evaluate modulation of drug uptake, cells were incubated at a density of 1 x 106/ml for 30 min at 37°C in RPMI 1640 with 10% fetal bovine serum and drug, with and without modulator. After 30-minute drug uptake, cells were washed once in cold PBS, resuspended in cold PBS, and kept on ice until analysis.
To study modulation of drug retention, after 30-min drug uptake without modulator, cells were resuspended in RPMI 1640 with 10% fetal bovine serum with and without modulator, and incubated at 37°C for 90 min. Cells were then pelleted, resuspended in ice cold PBS, and kept on ice until analysis.
Flow Cytometry.
Cellular content of the fluorescent drugs mitoxantrone, daunorubicin, doxorubicin, and topotecan was studied by flow cytometry. All of the samples were analyzed on a FacScan flow cytometer (Becton Dickinson, San Jose, CA) with an Argon laser for 488 nm excitation and 530/30 nm band-pass (FL1), 585/42 band-pass (FL2), and 670 long-pass (FL3) filters for emission collection. Flow cytometry data were analyzed using WinList software (Verity Software House, Topsham, ME).
Flow Cytometry Data Analysis.
Staining intensity was evaluated by comparing binding of each antibody with that of its matched isotype control with the Kolmogorov-Smirnov statistic, expressed as a D-value ranging from 0 (identical distribution histograms) to 1.0 (no overlap in distribution histograms; Ref. 26
). A D-value of 
0.2 is considered positive for staining with MRPm6, BXP-21, and BXP-34, because cell fixation is required before staining, increasing the background signal (19)
. A D-value of 0.1 is considered positive for staining with MRK16, which stains unfixed cells (21)
.
Modulation of drug uptake was measured by comparing cellular fluorescence after drug uptake with and without modulator both by the Kolmogorov-Smirnov statistic and by calculating the relative increase in mean fluorescence intensity (
MFI), as [(MFI with modulator - MFI without modulator)/MFI without modulator] x 100%. Modulation of drug retention was measured by comparing cellular fluorescence after 90-min efflux in the presence and absence of modulator (21)
both by the Kolmogorov-Smirnov statistic and by calculating MFI.
Although the MFI calculation provides a more immediately understood comparison of distribution histograms, the Kolmogorov-Smirnov statistic is a more sensitive measurement and, as such, has become a standard method of analysis of modulation of drug retention in clinical samples (21
, 25)
.
HPLC.
Cellular content of SN38 was studied by high-performance liquid chromatography (HPLC). SN38 was measured by a validated reverse phase HPLC method with fluorescence detection, using a modification of the method of Warner and Burke (27)
. SN38 was extracted from 2 x 106 cells in 400 µl of cold acidified methanol by brief sonication. After centrifugation of the cell debris, the supernatant was evaporated and the residue reconstituted in 200 µl of a 1:1 solution of acidified methanol and 3% triethylamine. Eighty µl of the supernatant were injected into the HPLC system, which consisted of a Waters Associates M600 pump, M717 autosampler, and M474 fluorescence detector operated by a computer with Waters Millenium software. The separation was carried out on a Waters Nova-Pak C18 column equipped with a µBondapak C18 guard column, with a mobile phase consisting of 20% acetonitrile and 80% triethylamine buffer (pH 5.5). The detection is by fluorescence, with excitation at 370 nm and emission at 510 nm. The standard curve range was 2.5–1000 ng/ml, with a limit of quantitation of 2.5 ng/ml.
Cytotoxicity Assays.
To study cytotoxicity in suspension cell lines, cells were plated in 96-well tissue culture plates at a density of 10,000 cells/well in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 20 units/ml penicillin, and 20 µg/ml streptomycin. Drug was added to the culture medium to achieve final concentrations of 0.3 nM to 10 µM, with half-log increments, with and without VX-710 at a final concentration of 2.5 µM. The final volume of medium per well was 100 µl. Cells were incubated for 96 h at 37°C in a fully humidified atmosphere of 5% CO2 in air. Cell growth was assessed by the WST-1 colorimetric assay (Roche Diagnostics GmbH, Mannheim, Germany; Ref. 29
), performed according to the manufacturer’s instructions. Briefly, 10 µl of WST-1 were added to each well, and culture plates were returned to the incubator for an additional 4 h. Subsequently, the absorbance at 450 nm (A450) and 600 nm (A600, background) was read for each well using a Microtek multiwell plate reader. Each drug exposure condition was assessed in quadruplicate.
To study cytotoxicity in adherent cell lines, cells were seeded at 600-2000 cells/well (cell line-dependent) in 96-well plates, and incubated for 18–24 h at 37°C to allow for attachment. Drugs were added to achieve final concentrations ranging from 0.3 nM up to 1 mM (cell line-dependent), with half-log increments, with and without 2.5 µM VX-710. Cells were incubated for 96 h at 37°C in a fully humidified atmosphere of 5% CO2 in air. Cell growth after 4 days of continuous drug exposure with and without modulator was also assessed by the WST-1 colorimetric assay. Each drug exposure condition was assessed in triplicate.
Cytotoxicity Data Analysis.
To determine the IC50, dose-dependent changes in absorbance (A450–A600) were evaluated using previously published curve-fitting software (30)
. The resistance-modifying factor (RMF) was calculated as the ratio [IC50 drug:IC50 (drug + modulator)].
Confocal Microscopy.
To determine the effect of VX-710 on the intracellular distribution of daunorubicin, 1 x 106 cells were incubated for 2 h with 5 µM daunorubicin and for 24 h with 0.5 µM daunorubicin in the presence and absence of 2.5 µM VX-710, and then were washed with PBS. Cell pellets were resuspended in 200 µl of ice-cold PBS, and 10-µl aliquots were transferred to glass microscope slides coated with 0.2% (w/v) alcian blue to improve cell adherence. The specimens were mounted with Vectashield (Vector Labs) and evaluated by confocal microscopy. The excitation light source was set at 488 nm, and emission was captured through a 550-nm long-pass filter. For each cell, 10–20 focal planes were evaluated, and planes representing the optimal nuclear:cytoplasmic ratios were stored.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Wild-type HL60 cells did not stain with antibodies to any of the three proteins. 8226/Dox6 and A2780/Dx5b cells expressed Pgp, HL60/Adr cells expressed MRP-1, and BCRP expression was confirmed in 8226/MR20 and MCF7 AdVp3000 cells. Wild-type 8226, MCF7, and 8226/Dox6 cells also expressed BCRP, as reported previously (19
, 20)
. Thus, 8226/Dox6 cells coexpressed Pgp and BCRP, whereas A2780/Dx5b cells expressed only Pgp. Of note, BCRP antibody staining does not distinguish between wild-type and mutant forms of the protein.
|
First, to demonstrate that VX-710 itself is not fluorescent, HL60 cells were incubated in medium with increasing VX-710 concentrations, up to 10 µM. With the FacScan instrument settings used to detect mitoxantrone, VX-710-associated fluorescence was not detected (data not shown).
VX-710 effectively modulated mitoxantrone uptake in cell lines expressing Pgp, MRP-1, and BCRPR482 (Fig. 1)
. In A2780/Dox5b (Pgp), 8226/Dox6 (Pgp and BCRPR482), HL60/Adr (MRP-1), and 8226/MR20 (BCRPR482) cells, the presence of VX-710 increased mitoxantrone uptake by 74% (D = 0.51), 55% (D = 0.49), 43% (D = 0.71), and 60% (D = 0.37). In comparison with transport protein-specific modulators, VX-710 was less effective than PSC-833 (D = 0.91 and MFI 255% in A2780/Dx5b cells), probenecid (D = 0.95 and MFI 330% in HL60/ADR cells), and FTC (D = 0.83 and MFI 200% in 8226/MR20 cells) in modulating mitoxantrone uptake. In 8226/Dox6 cells, it was less effective than PSC-833 (D = 0.85 and MFI 150%), but more effective than FTC (D = 0.33 and MFI 27%) in modulating mitoxantrone uptake.
|
. In A2780/Dox5b (Pgp), 8226/Dox6 (Pgp and BCRPR482), HL60/Adr (MRP-1), and 8226/MR20 (BCRPR482) cells, the presence of VX-710 increased mitoxantrone retention by 60% (D = 0.5), 100% (D = 0.53), 90% (D = 0.55) and 40% (D = 0.34). In comparison with transport protein-specific modulators, VX-710 modulated mitoxantrone retention similarly to PSC-833 (D = 0.5 and MFI 60% in A2780/Dx5b cells) but less effectively than probenecid (D = 0.79 and MFI 200% in HL60/ADR cells) and FTC (D = 0.71 and MFI 140% in 8226/MR20 cells). In 8226/Dox6 cells (Pgp and BCRPR482), VX-710 modulated mitoxantrone retention more effectively than both PSC-833 (D = 0.33 and MFI 20%) and FTC (D = 0.38 and MFI 60%).
|
, but modulated mitoxantrone retention (Fig. 2)
, consistent with the previously described chemosensitizing effects of VX-710 at 2.5 µM in several drug-sensitive parental cell lines (13)
. In contrast, PSC-833, probenecid and FTC had no effect on mitoxantrone retention in HL60 cells (Fig. 2)
.
Because daunorubicin is a mainstay of therapy for acute myeloid leukemia (AML) and has been the substrate drug in MDR modulation clinical trials in AML (21
, 30)
and because AML cells express Pgp, MRP-1 and BCRPR482 (8)
, VX-710 modulation of daunorubicin transport was also studied in cell lines overexpressing these proteins. VX-710 effectively modulated daunorubicin uptake and retention (Table 2)
in cell lines overexpressing Pgp (8226/Dox6) and MRP-1 (HL60/ADR). In contrast, VX-710 only slightly increased daunorubicin uptake (D = 0.17 and MFI 10%) and retention (D = 0.13 and MFI 10%) in 8226/MR20 cells, consistent with the fact that these cells express BCRPR482, which does not transport daunorubicin (7)
. VX-710 slightly increased daunorubicin uptake in HL60 cells (D = 0.35, MFI 20%), but had no effect on retention (D = 0.04, MFI = 5%). Like modulation of mitoxantrone retention, modulation of daunorubicin uptake may be consistent with the previously described chemosensitizing effects of VX-710 at 2.5 µM in several drug-sensitive parental cell lines (13)
.
|
. IC50s were determined in the absence and presence of 2.5 µM VX-710, and the RMF was calculated as the ratio of the IC50 with drug alone to that with drug and modulator.
|
As shown in Fig. 3
, in concordance with the drug uptake and retention data, VX-710 sensitized cell lines expressing Pgp (8226/Dox6) and MRP-1 (HL60/ADR) to mitoxantrone, with RMFs of 3.1 and 2.4, respectively, and also sensitized these cell lines to daunorubicin, with RMFs of 6.9 and 3.3, respectively. VX-710 also sensitized 8226/MR20 cells, which overexpress BCRPR482, to mitoxantrone, with a RMF of 2.4. Moreover, VX-710 sensitized 8226/MR20 cells to daunorubicin, with a RMF of 3.6, although only minimally increased daunorubicin retention in these cells. Finally, whereas VX-710 increased retention of mitoxantrone and daunorubicin in HL60 cells, it had no effect on cytotoxicity.
|
shows representative examples of cellular daunorubicin distribution in 8226/MR20 cells after 2-h drug exposure to daunorubicin with and without VX-710.
|
, as are the effects of FTC. Whereas the presence of FTC significantly enhanced the retention of all four drugs in this cell line (D = 0.47, 0.67, 0.37, and 0.32 for mitoxantrone, daunorubicin, doxorubicin, and topotecan, respectively), VX-710 had only minimal effects (D = 0.05, 0.26, 0.15 and 0.06 for mitoxantrone, daunorubicin, doxorubicin and topotecan, respectively). Because MCF7 AdVp3000 cells very efficiently transport drugs out of the cells, retention with and without modulator was studied after uptake both in the presence and absence of modulator. The presence of VX-710 had little or no effect on uptake, and its presence during uptake had no effect on subsequent retention. Moreover, although the presence of FTC significantly enhanced uptake, the extent of modulation of retention by FTC was not significantly affected by its presence during uptake. Additionally, as measured by HPLC (Fig. 5B)
, VX-710 did not increase uptake of SN38 (2.18 ng/1 x 106 cells in the presence of VX-710 versus 2.9 ng/1 x 106 cells in the absence of modulator), whereas FTC markedly increased its uptake (13.98 ng/1 x 106 cells). Finally (Fig. 6)
, VX-710 had little effect on mitoxantrone, daunorubicin, doxorubicin, topotecan, or SN38 cytotoxicity in MCF7 AdVp3000 cells, whereas FTC markedly increased cytotoxicity of all five drugs. Thus, in contrast to FTC, VX-710 does not modulate retention or cytotoxicity of substrate drugs in MCF7 AdVp3000 cells, which overexpress BCRPR482T. In MCF7 parental cells, VX-710, like PSC-833, probenecid and FTC, had no effect on mitoxantrone uptake, retention ( MFI = 0 for all modulators), or cytotoxicity.
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Although effective against BCRPR482, VX-710 was ineffective against BCRPR482T. The latter is expressed in MCF7 AdVp3000 breast cancer cells, in which BCRP was initially described (4) but, thus far, has not been found in clinical samples. Specifically, BCRPR482 has been found in all cases of both AML (8) and acute lymphoblastic leukemia (9) studied to date. Thus, based on knowledge to date, the lack of effect on BCRPR482T should not compromise the efficacy of VX-710 as a clinical broad-spectrum modulator. The amino acid at position 482 of the BCRP protein is known to determine its substrate specificity (7) ; based on the data presented here, the amino acid at position 482 is also critical in determining modulator specificity.
In direct comparisons with MDR protein-specific modulators in the present study, VX-710 was as potent as PSC-833 in modulating Pgp, slightly less potent than probenecid in modulating MRP-1, and less potent than FTC in modulating BCRPR482. In this regard, it should be noted that probenecid and FTC are not suitable for development as clinical MDR modulators because of toxicities associated with their use at the concentrations required for modulation. VX-710 had been previously demonstrated to be as effective as cyclosporine A (CsA) in modulating Pgp, and 
2-fold more effective than CsA in modulating MRP-1 (14)
. VX-710 had also been found to be a more effective modulator than PSC-833 and CsA in neuroblastoma cell lines expressing Pgp, MRP-1, and lung resistance protein (32)
. Although less potent than specific MRP-1 and BCRP modulators, VX-710 has the advantages of efficacy against all three MDR-associated drug efflux pumps and of clinical applicability.
Both specific and broad-spectrum modulators have theoretical advantages for clinical MDR modulation. Clinical MDR appears to be multifactorial, and effective modulation may require targeting of multiple transport proteins. The use of a single broad-spectrum modulator may be preferable to the use of combinations of specific modulators to prevent drug interactions and cumulative toxicities. On the other hand, the use of specific modulators might minimize unwanted modulation of nontargeted transporters and minimize effects on nontumor tissues such as normal hematopoietic stem cells, bile canaliculi, and the blood-brain barrier. Clinical application of broad-spectrum modulation warrants testing in clinical trials with correlative laboratory studies.
Despite the theoretical concerns about potential toxicities of broad-spectrum modulation, VX-710 has been very well tolerated in clinical experience to date. Doses of VX-710 that produce plasma concentrations sufficient for complete MDR reversal in vitro have not been associated with toxicity (33) .
In addition to being well tolerated, another advantage of VX-710 as a clinical modulator is its relative lack of pharmacokinetic interactions. VX-710 has been found to have minimal or no effects on the pharmacokinetics of doxorubicin (34 , 35) and mitoxantrone (36) , although it does alter paclitaxel pharmacokinetics (33 , 37 , 38) . Thus, anthracycline dose reductions should not be required when these drugs are administered in combination with VX-710. The lack of substantial pharmacokinetic interaction of VX-710 with doxorubicin makes it an attractive agent for clinical MDR modulation in AML and other malignancies in which anthracyclines are mainstays of therapy.
Approaches to reversal of clinical MDR in AML have thus far yielded variable and generally disappointing results. Limitations of clinical trials have included modulator-associated toxicities and toxicities caused by modulator-associated pharmacokinetic interactions with chemotherapy drugs (21) . The most successful clinical trial in leukemia to date has been the Southwest Oncology Group phase III CsA trial, in which remission duration and survival were prolonged significantly in patients with refractory and relapsed AML who received chemotherapy with CsA, compared with chemotherapy without CsA (30) . In this trial, daunorubicin was administered by continuous infusion, which may have avoided high peak levels and, thus, averted enhanced toxicity associated with pharmacokinetic interaction with CsA. Additionally, CsA may also be more effective than PSC-833 by virtue of partial efficacy against MRP-1 (14) .
Finally, based on the data presented here, VX-710 may have other chemosensitizing effects in addition to those resulting from modulation of drug retention mediated by Pgp, MRP-1, or BCRPR482. In addition to increasing drug retention in cell lines overexpressing these three ATP-binding cassette transport proteins, VX-710 also increased mitoxantrone retention in HL60 cells. The increase in mitoxantrone retention in HL60 cells in our study was not associated with an increase in cytotoxicity, although VX-710 at 2.5 µM was previously found to have modest chemosensitizing effects in several drug-sensitive parental cell lines (13) . VX-710 also sensitized 8226/MR20 cells to daunorubicin in the absence of enhanced drug retention or altered nuclear-cytoplasmic drug distribution. Thus, VX-710 may also modulate drug retention and chemosensitivity by unknown mechanisms in addition to modulation of MDR proteins. There is at least one precedent for the existence of MDR protein-independent effects of MDR modulators, in that the Pgp modulator PSC-833 has been demonstrated to have Pgp-independent pro-apoptotic effects in AML cells (39) .
Broad-spectrum modulation, lack of significant toxicity, and lack of significant pharmacokinetic interactions with anthracyclines (34 , 35) and mitoxantrone (36) are significant advantages of VX-710, supporting its further development as a clinical modulator. The activity of VX-710 as a modulator is not restricted to leukemias, as evidenced by clinical trials combining VX-710 with paclitaxel, in which resensitization of paclitaxel-refractory epithelial tumors was demonstrated (37 , 38) . Nevertheless, VX-710 appears particularly attractive for further study in AML, because AML cells may express all three MDR-associated drug efflux proteins (8 , 15) , and anthracyclines are a mainstay of therapy.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Maria R. Baer, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: (716) 845-5975; Fax: (716) 845-8446; E-mail: maria.baer{at}roswellpark.org
Received 6/19/03; revised 10/20/03; accepted 11/17/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  R. W. Robey, A. Lazarowski, and S. E. Bates P-Glycoprotein--a Clinical Target in Drug-Refractory Epilepsy? Mol. Pharmacol., May 1, 2008; 73(5): 1343 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, M. Konopleva, Y.-x. Shi, T. McQueen, D. Harris, X. Ling, Z. Estrov, A. Quintas-Cardama, D. Small, J. Cortes, et al. Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia J Natl Cancer Inst, February 6, 2008; 100(3): 184 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Henrich, H. R. Bokesch, M. Dean, S. E. Bates, R. W. Robey, E. I. Goncharova, J. A. Wilson, and J. B. McMahon A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity J Biomol Screen, March 1, 2006; 11(2): 176 - 183. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Tabe, M. Konopleva, R. Contractor, M. Munsell, W. D. Schober, L. Jin, Y. Tsutsumi-Ishii, I. Nagaoka, J. Igari, and M. Andreeff Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells Blood, February 15, 2006; 107(4): 1546 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Walter, J. L. Pirga, M. R. Cronk, S. Mayer, F. R. Appelbaum, and D. E. Banker PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism Blood, November 15, 2005; 106(10): 3584 - 3593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Qadir, K. L. O'Loughlin, S. M. Fricke, N. A. Williamson, W. R. Greco, H. Minderman, and M. R. Baer Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator Clin. Cancer Res., March 15, 2005; 11(6): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
